Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib in Relapsing-Remitting Multiple Sclerosis
NCT04711148Phase 2Active, not recruiting
- Sponsor
- InnoCare Pharma
- Start
- Mar 2021
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of orelabrutinib in relapsing-remitting multiple sclerosis (RRMS), sponsored by InnoCare Pharma. Started Mar 2021; status: active, not recruiting.
02
Drugs
orelabrutinib
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT04711148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04711148.